Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
NRXP Catalyst Timeline
Dated clinical, regulatory and corporate events for NRX Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for NRX Pharmaceuticals, Inc.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How NRXP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-30 | NRX-100 (preservative-free intravenous ketamine) | PDUFA Date Approved | PDUFA |
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NRX-101 Small MoleculesNCT07227103 | Treatment Resistant Depression | Phase 2/3 | RECRUITING | 240 | Jun 30, 2028 | ||||||
| NRX-101 Small MoleculesCompletedNCT02974010 | Bipolar Depression | Phase 2/3 | COMPLETED | 104 | Nov 20, 2019 |
Clinical Trial Results
Readouts, endpoints and source filings for every NRXP program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| IV ketamine Fast Track | treatment resistant depression | 2026-06-05 | remission rate iv: 34%; response rate iv: 63%; remission rate nasal esketamine: 26%; response rate nasal esketamine: 58%; odds ratio remission: 1.51; p value remission: <.001; odds ratio response: 1.22; p value response: <.003Read More | NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Javitt Jonathan CDirector, Officer (Chairman and Chief Scientist), 10% Owner | Buy | 40,000 84,634 held | $1.17 | 12/17/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in NRXP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in NRXP for Q3 2026. | ||||
Ownership Trends
NRXP Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How NRXP ranks across every disease it competes in
NRXP News
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Third Quarter 2026 Financial Results and Provides Corporate Update
NRx Pharmaceuticals reported its third quarter 2026 financial results, highlighting FDA approval of its first drug, preservative-free ketamine. The company has initiated a commercial launch with a 17-person sales team and expects significant market growth. Additionally, NRx announced a collaboration with Yale University to support NRX-100's Accelerated Approval and introduced a new product, NRX-200, for subcutaneous delivery.
Read more →NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2026 Financial Results and Provide Corporate Update
NRx Pharmaceuticals will report its Q3 2026 financial results on November 17, 2026. The company has received significant designations for its drugs, including Fast Track and Breakthrough Therapy for NRX-100 and NRX-101. Additionally, it secured an $11.25 million contract for a phase 3 trial of NRX-101.
Read more →NRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running Shortage
NRx Pharmaceuticals has begun selling a new preservative-free ketamine, addressing a shortage that has persisted since 2018. The product is manufactured in the U.S. and utilizes innovative BFS technology, enhancing safety and efficiency. Initial supply agreements are expected by late 2026, with shipments starting in January 2027.
Read more →NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date
NRx Pharmaceuticals received FDA approval for Preservative-Free Ketamine before the November 10 goal date. This new formulation eliminates the toxic preservative benzethonium chloride, addressing a significant safety concern. The company aims to reshore sterile drug manufacturing in the U.S. to alleviate the current ketamine shortage.
Read more →NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine
NRx Pharmaceuticals will host a conference call on October 30, 2026, to discuss a regulatory milestone for its Preservative-Free Ketamine program. The call will cover next steps for the commercial launch. The company has also received an $11.25 million contract for a phase 3 trial of NRX-101, aimed at treating depression.
Read more →NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine
NRx Pharmaceuticals has completed the manufacturing process validation for preservative-free Ketamine, ensuring compliance with FDA Good Manufacturing Practices. The company also announced positive two-year stability data, indicating the drug's quality remains intact without toxic preservatives. This positions NRx to supply the product immediately following FDA approval of their ANDA.
Read more →NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine
NRx Pharmaceuticals has received a Discipline Review Letter from the FDA requesting minor changes to the labeling of its preservative-free ketamine product. The company is required to submit sample labels with the proprietary name under review ahead of the GDUFA goal date of November 10, 2026. NRx is also completing final manufacturing process validation runs for the product launch.
Read more →NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression
NRx Defense Systems has secured an $11 million DARPA contract to evaluate a novel treatment for resistant depression using robotic TMS and NRX-101. The SPARC-TMS trial aims to validate a one-day treatment protocol that could revolutionize care for military personnel and others suffering from depression. This initiative builds on promising earlier studies showing significant treatment response rates.
Read more →NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine
NRx Pharmaceuticals has announced that the FDA has reclassified its ANDA amendment for preservative-free ketamine from a Major Amendment to a Minor Amendment. This change has also led to a revision of the GDUFA goal date to November 10, 2026. The company views this as a positive development that may facilitate a quicker approval process for their product.
Read more →GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)
GeNeuro, Inc. has been awarded a European Patent for GNK-301, a monoclonal antibody aimed at treating Amyotrophic Lateral Sclerosis (ALS). The patent covers the discovery that the HERV K Envelope protein is present in the spinal fluid of many ALS patients and is neurotoxic. The company plans to start Phase I trials in 2027, marking a significant step in ALS treatment development.
Read more →NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System
NRx Pharmaceuticals' subsidiary, HOPE Therapeutics, is set to deploy the FDA-cleared Zeta TMS Robotic System, enhancing treatment precision for patients with depression. The clinical team is currently training in Boston, and the deployment will support the SPARC-TMS trial of NRX-101. This advancement aims to improve patient outcomes in both military and civilian settings.
Read more →NRx Pharmaceuticals to Participate in Upcoming Investor Conferences
NRx Pharmaceuticals will participate in three investor conferences in September 2026, showcasing its clinical-stage developments. CEO Jonathan Javitt will present at the Moody Capital Solutions Conference, the Cantor Global Healthcare Conference, and the H.C. Wainwright Global Investment Conference. The company is focused on developing therapies for central nervous system disorders.
Read more →NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET
NRx Pharmaceuticals reported its financial results for Q2 2026, highlighting significant advancements in its drug development programs. The company completed the FDA review for preservative-free ketamine and initiated commercial manufacturing. Additionally, NRx was selected by DARPA for a Phase 2/3 trial of NRX-101, aiming for broader treatment applications. Financially, the company reported a net loss but secured substantial funding to support operations.
Read more →NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans
NRx Pharmaceuticals announced a conference call on August 10, 2026, to discuss the FDA's completion of the first-cycle review of its ANDA for preservative-free ketamine. Key executives will participate, addressing regulatory pathways and commercial plans. The call will be accessible via webcast and telephone, with a replay available afterward.
Read more →FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval
NRx Pharmaceuticals announced that the FDA has completed the first-cycle review of its preservative-free ketamine ANDA, identifying no major deficiencies. The only remaining requirement is a certification related to the medication vial's luer lock tip. NRx views this outcome as a significant regulatory milestone that reduces risks for commercialization. A conference call is scheduled for August 10, 2026, to discuss further developments.
Read more →NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute
NRx Pharmaceuticals has responded to Kadima Neuropsychiatry Institute's recent allegations regarding a failed acquisition by HOPE Therapeutics. NRx has initiated arbitration due to Kadima's failure to meet key conditions. The company emphasizes its focus on drug development and innovative treatments, particularly in personalized medicine and TMS technology, despite the ongoing dispute.
Read more →NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
NRx Pharmaceuticals' subsidiary, HOPE Therapeutics, has initiated treatments using the FDA-cleared Zeta TMS Navigation System at its clinics in Florida. This marks a significant transition to active patient care, utilizing AI for precise targeting in TMS therapies for Major Depressive Disorder and other CNS conditions. The deployment supports HOPE's interventional psychiatry platform and aligns with planned clinical trials for NRX-101.
Read more →ZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics
ZETA SURGICAL and HOPE Therapeutics announced the successful treatment of the first patient using the Zeta TMS Navigation System, which is FDA-cleared. This system utilizes advanced AI and computer vision for precise targeting in TMS therapy, primarily for treatment-resistant depression. The technology aims to enhance patient outcomes and expand access to personalized care.
Read more →NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression
NRx Pharmaceuticals has received FDA approval for an Expanded Access Protocol for NRX-101, a combination of D-cycloserine and lurasidone, aimed at augmenting Transcranial Magnetic Stimulation (TMS) for patients with Treatment-Resistant Depression. This protocol allows patients who cannot participate in clinical trials to access the treatment. The company is also conducting a pivotal trial to assess the efficacy of NRX-101 in achieving remission from depression and suicidality.
Read more →NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.
NRx Pharmaceuticals announced a presentation at the American Society of Clinical Psychopharmacology, highlighting a study comparing IV ketamine and nasal esketamine for treating depression. The study found that IV ketamine resulted in higher remission and response rates among patients. However, it noted limitations due to non-randomized treatment assignments and potential confounding variables.
Read more →